Shivaani Kummar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shivaani Kummar has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
A Canova
Department of Medicine, Yale Cancer Center, Yale University School of Medicine and VA Connecticut Cancer Center, VA Connecticut Healthcare System, 950 Campbell Avenue, 111D, West Haven, Connecticut, CT 06516, USA
1 shared publicationA Mota
Department of Medicine, Yale Cancer Center, Yale University School of Medicine and VA Connecticut Cancer Center, VA Connecticut Healthcare System, 950 Campbell Avenue, 111D, West Haven, Connecticut, CT 06516, USA
1 shared publicationM Fogarasi
Department of Medicine, Yale Cancer Center, Yale University School of Medicine and VA Connecticut Cancer Center, VA Connecticut Healthcare System, 950 Campbell Avenue, 111D, West Haven, Connecticut, CT 06516, USA
1 shared publication- Miklos C. Fogarasi
Department of Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, USA
1 shared publication N.Q. Shafi
1 shared publicationT Ciesielski
Department of Pathology, VA Connecticut Healthcare System, West Haven, Connecticut, USA
1 shared publication
Latest Publications
- 1 August 2003
- Published by Elsevier in Clinical Oncology
- Vol. 15 (5) , 288-294
Metastatic Hepatocellular Carcinoma
- 1 August 2003
- Published by Elsevier in Clinical Oncology
- Vol. 15 (5) , 288-294
Metastatic Hepatocellular Carcinoma
- 1 October 2002
- Vol. 16 (10) , 1364
Management of small bowel adenocarcinoma.
Small bowel adenocarcinoma is a relatively rare malignancy. Only limited information is available on the incidence, prognosis, and role of chemotherapy in the treatment of this disease. We present a review of currently available clinical data to assist the practicing oncologist in the treatment of these patients. Approximately 5,300 new cases and 1,100 deaths from small bowel adenocarcinoma are reported annually in the United States. Increased incidence is seen in patients with Crohn's disease, hereditary nonpolyposis colorectal cancer, and familial adenomatouspolyposis. Factors associated with poor prognosis are age > 75 years, lack of surgical resection, advanced stage, and tumor arising in the duodenum. The median survival of patients with localized, locally advanced, and metastatic disease is 50.1, 22.2, and 8.6 months, respectively. Few data exist on the use of (neo)adjuvant or palliative chemo(radio)therapy in this setting. Fluorouracil (5-FU)based chemotherapy, as a single agent or in combination with others, has been used in most case series. Duodenal adenocarcinoma accounts for more than 50% of all cases of small bowel adenocarcinoma. Resectability is the key prognostic factor, along with age, performance status, tumor location, and presence of distant metastasis. Although the activity of 5-FU-based regimens has been documented, the assessment of clinical benefit is hindered by the lack of prospective, randomized data.
- 1 October 2002
- Vol. 16 (10) , 1364
Management of small bowel adenocarcinoma.
Small bowel adenocarcinoma is a relatively rare malignancy. Only limited information is available on the incidence, prognosis, and role of chemotherapy in the treatment of this disease. We present a review of currently available clinical data to assist the practicing oncologist in the treatment of these patients. Approximately 5,300 new cases and 1,100 deaths from small bowel adenocarcinoma are reported annually in the United States. Increased incidence is seen in patients with Crohn's disease, hereditary nonpolyposis colorectal cancer, and familial adenomatouspolyposis. Factors associated with poor prognosis are age > 75 years, lack of surgical resection, advanced stage, and tumor arising in the duodenum. The median survival of patients with localized, locally advanced, and metastatic disease is 50.1, 22.2, and 8.6 months, respectively. Few data exist on the use of (neo)adjuvant or palliative chemo(radio)therapy in this setting. Fluorouracil (5-FU)based chemotherapy, as a single agent or in combination with others, has been used in most case series. Duodenal adenocarcinoma accounts for more than 50% of all cases of small bowel adenocarcinoma. Resectability is the key prognostic factor, along with age, performance status, tumor location, and presence of distant metastasis. Although the activity of 5-FU-based regimens has been documented, the assessment of clinical benefit is hindered by the lack of prospective, randomized data.
- Open Access
- 11 June 2002
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (12) , 1884-1887
Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma
The origin of metastatic adenocarcinoma lesions can sometimes be difficult to diagnose. The objectives of our study were to establish the cytokeratin staining pattern of primary and metastatic lung and colorectal adenocarcinomas, and to determine if this helps to identify the site of origin of metastatic lesions. We reviewed a total of 102 tissue samples from patients in our tumour registry, with either primary or metastatic lung or colorectal adenocarcinoma. Tissue sections were stained for cytokeratin 7 and 20 and read as positive or negative for staining. Clinical and radiologic information was reviewed from computerised charts. The cytokeratin 7+/cytokeratin 20- pattern characterised 96% (29 out of 30) of primary and 95% (21 out of 22) of metastatic lung adenocarcinomas. All the primary (26), and 88% (21 out of 24) of metastatic colorectal adenocarcinomas stained cytokeratin 7-/cytokeratin 20+. Samples from a variety of metastatic sites were evaluated for cytokeratin 7 and 20 staining. Out of the 102 samples, in 95% (97 out of 102) of the cases, the cytokeratin 7 and cytokeratin 20 staining pattern characterised and differentiated between lung and colorectal adenocarcinoma. Primary and metastatic lung adenocarcinomas show a cytokeratin 7+/cytokeratin 20- staining pattern, while colorectal adenocarcinomas stain cytokeratin 7-/cytokeratin 20+. Cytokeratin staining is helpful in the diagnostic differentiation of metastatic lesions from these two common primaries, and assists in determining the site of origin of metastatic lesions.
- 11 June 2002
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (12) , 1884-1887
Open AccessCytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma
The origin of metastatic adenocarcinoma lesions can sometimes be difficult to diagnose. The objectives of our study were to establish the cytokeratin staining pattern of primary and metastatic lung and colorectal adenocarcinomas, and to determine if this helps to identify the site of origin of metastatic lesions. We reviewed a total of 102 tissue samples from patients in our tumour registry, with either primary or metastatic lung or colorectal adenocarcinoma. Tissue sections were stained for cytokeratin 7 and 20 and read as positive or negative for staining. Clinical and radiologic information was reviewed from computerised charts. The cytokeratin 7+/cytokeratin 20- pattern characterised 96% (29 out of 30) of primary and 95% (21 out of 22) of metastatic lung adenocarcinomas. All the primary (26), and 88% (21 out of 24) of metastatic colorectal adenocarcinomas stained cytokeratin 7-/cytokeratin 20+. Samples from a variety of metastatic sites were evaluated for cytokeratin 7 and 20 staining. Out of the 102 samples, in 95% (97 out of 102) of the cases, the cytokeratin 7 and cytokeratin 20 staining pattern characterised and differentiated between lung and colorectal adenocarcinoma. Primary and metastatic lung adenocarcinomas show a cytokeratin 7+/cytokeratin 20- staining pattern, while colorectal adenocarcinomas stain cytokeratin 7-/cytokeratin 20+. Cytokeratin staining is helpful in the diagnostic differentiation of metastatic lesions from these two common primaries, and assists in determining the site of origin of metastatic lesions.
- 1 November 2001
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 1 (3) , 187-188
Cytokeratin Staining for Primary and Metastatic Colorectal Cancer
- 1 November 2001
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 1 (3) , 187-188
Cytokeratin Staining for Primary and Metastatic Colorectal Cancer